Drug intelligence / Profile preview

diantican sodium

Development stage: Unknown
Lead developer: Fangsheng Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

Diantican sodium (FS-1101) is a novel, water-soluble camptothecin derivative developed by Hunan Fangsheng Pharmaceutical. It functions as a DNA topoisomerase I (TOP1) inhibitor, a class of drugs that interferes with the DNA replication process by stabilizing the TOP1-DNA cleavable complex. This stabilization prevents the re-ligation of DNA strands, resulting in permanent double-strand breaks and subsequent cell death. Diantican sodium is being developed for the treatment of advanced solid tumors, with a focus on colorectal, gastric, breast, and lung cancers. It aims to provide a more favorable solubility and safety profile compared to existing camptothecin analogues like irinotecan.

Other names: Dian-Ti-Can sodium典替康钠

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on diantican sodium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diantican sodium.

Explore the full profile